CSIMarket
 
Biogen Inc   (BIIB)
Other Ticker:  
 
 
Price: $219.4000 $0.09 0.041%
Day's High: $220.56 Week Perf: -3.5 %
Day's Low: $ 218.96 30 Day Perf: -1.77 %
Volume (M): 42 52 Wk High: $ 319.76
Volume (M$): $ 9,176 52 Wk Avg: $262.93
Open: $220.34 52 Wk Low: $215.35



 Market Capitalization (Millions $) 31,963
 Shares Outstanding (Millions) 146
 Employees 9,610
 Revenues (TTM) (Millions $) 9,836
 Net Income (TTM) (Millions $) 1,162
 Cash Flow (TTM) (Millions $) -2,405
 Capital Exp. (TTM) (Millions $) 311

Biogen Inc
Biogen Idec creates new standards of care in oncology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, we transform scientific discoveries into advances in human healthcare. We currently have four commercial products: AVONEX' (Interferon beta-1a) for the treatment of relapsing multiple sclerosis, also known as MS, RITUXAN' (rituximab)'and ZEVALIN' (ibritumomab tiuxetan), both of which treat certain B-cell non-Hodgkin's lymphomas, also referred to as B-cell NHLs, and AMEVIVE' (alefacept)'for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.


   Company Address: 225 Binney Street Cambridge 2142 MA
   Company Phone Number: 679-2000   Stock Exchange / Ticker: NASDAQ BIIB
   


Customers Net Income fell by BIIB's Customers Net Profit Margin fell to

-11.5 %

2.66 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -2.04%    
ABBV   -1.34%    
ABT   -6.89%    
BMY   -5.17%    
JNJ   -3.67%    
MRK   -0.99%    
• View Complete Report
   



Clinical Study

New Biomarker Data Supports SPINRAZA Effectiveness in Infants and Toddlers with Spinal Muscular Atrophy

Published Wed, Mar 6 2024 12:31 PM UTC

Biogen Inc., a leading biopharmaceutical company, has recently announced significant interim biomarker data that further supports the potential benefits of SPINRAZA (nusinersen) in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after gene therapy. This breakthrough therapy has shown promise in addressing axonal injury and neurodegenerat...

Product Service News

Biogen's QALSODY (tofersen) Receives Positive CHMP Opinion as First-Ever Therapy for Rare Genetic ALS

Published Fri, Feb 23 2024 12:00 PM UTC

Biogen Inc. (Nasdaq: BIIB) has recently announced a groundbreaking development in the treatment of amyotrophic lateral sclerosis (ALS), commonly known as motor neuron disease (MND). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a marketing authorization under exceptional circumstances for QALSODY (tofersen). ...

Biogen Inc

Soft Top-line Growth Marks a Challenging Quarter for Biogen Inc as Financial Performance Declines across Key Metrics

Biogen Inc, a leading biotechnology and pharmaceuticals company, has reported its financial results for the fourth quarter of 2023. The income per share for the quarter plummeted by -55.59% to $1.70 per share, compared to $3.83 per share in the same period last year. However, there was a positive improvement from the preceding quarter where the income per share was $-0.47 per share.
The revenue for the fourth quarter of 2023 also saw a decrease of -6.199% to $2.39 billion from $2.54 billion in the same quarter a year ago. Sequentially, the revenue decreased by -5.691% from $2.53 billion. The earnings for the quarter fell by -54.7% to $248.900 million compared to $549.500 million in the corresponding period a year before.
When looking at the profitability of Biogen Inc in the fourth quarter of 2023, the operating margin mitigated to 24.21% and the net margin shrank to 10.43%. The inventories declined to $2,527.4 million from the previous quarter but increased relative to the same period a year ago. Furthermore, the operating earnings fell by -19.42% to $577.7 million, resulting in a decrease in Biogen Inc's operating margin.

Product Service News

Biogen's SKYCLARYS Approved as First Treatment for Friedreich's Ataxia and ZURZUVAE Offers Groundbreaking Relief for Postpartum Depression

Published Mon, Feb 12 2024 9:06 PM UTC

Biogen Receives European Commission Approval for SKYCLARYS (omaveloxolone) as the First Treatment for Friedreich's Ataxia, While ZURZUVAE (zuranolone) CIV Offers a Landmark Oral Treatment for Postpartum Depression in the U.S.Biogen, a leading biotechnology company, has recently achieved a significant advance in the field of neurodegenerative diseases with the European Commis...

Clinical Study

Biogen Inc. Announces Reorganization to Advance Alzheimer's Disease Therapies

Published Wed, Jan 31 2024 12:30 PM UTC

In a recent announcement, Biogen Inc. revealed its strategic plans to reprioritize resources within the field of Alzheimer's disease (AD), aiming to drive growth in the near and long-term. The pharmaceutical giant will continue advancing LEQEMBI (lecanemab-irmb), the first anti-amyloid beta treatment with FDA traditional approval in the United States, while also accelerating...






 

Biogen Inc's Segments
 
AVONEX
 Segment     of total Revenue
TYSABRI
 Segment     of total Revenue
PLEGRIDY
 Segment     of total Revenue
Other
 Segment     of total Revenue
FAMPYRA
 Segment     of total Revenue
TECFIDERA
 Segment     of total Revenue
ALPROLIX
 Segment     of total Revenue
ELOCTATE
 Segment     of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Biogen Inc announced annual revenue outlook on

Earnings Outlook
Biogen Inc issued annual earnings guidance on

 
Geographic Revenue Dispersion
United States
Europe
Asia
Other




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com